[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Alves AP, Pessoa Cdo O, Costa-Lotufo L, Moraes Filho MO: Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma. Acta Cir Bras; 2007 Nov-Dec;22(6):457-64
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma.
  • PURPOSE: To investigate the effects of bisphosphosnate alendronate (ALD) and metotrexate (MTX) on an experimental model of Walker 256 carcinosarcoma developed in the oral cavity of rats.
  • METHODS Walker 256 carcinosarcoma cell suspension (0,1 mL) containing 10(6) cell/mL was implanted in the alveoli of the first and second molars.
  • CONCLUSION: The bisphosphonate alendronate exherted an osteoprotective effect and induced bone neoformation on the Walker 256 carcinosarcoma inoculated in rat mandibles.
  • The combination of metotrexate with bisphosphonate alendronate is more successful than treatment with the agents alone in controlling the growth of neoplastic cells and in stimulating reactive new bone.
  • Therefore, this may be an alternative treatment to malignant lesions of maxillaries with osteolysis.

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235934.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; X1J18R4W8P / Alendronate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Brito NM, Brito MV, Carvalho Rde K, Matos LT, Lobato RC, Correa SC, Brito RB: The effect of copaiba balsam on Walker 256 carcinoma inoculated into the vagina and uterine cervix of female rats. Acta Cir Bras; 2010 Apr;25(2):176-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of copaiba balsam on Walker 256 carcinoma inoculated into the vagina and uterine cervix of female rats.
  • PURPOSE: To verify the copaiba balsam (Copaifera officinalis) effect on Walker 256 carcinoma inoculated into vagina and uterine cervix of rats.
  • On the 1st day of the experiment, 0.3 ml of Walker 256 carcinoma (2x10(6) concentration) was inoculated in both groups; on the 3rd day of the experiment, it was given 4.8 ml/kg of distilled water to the GC group, and 4.8 ml/kg of copaiba balsam to the GCop group.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305885.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Balsams; 0 / copaiba balsam
  •  go-up   go-down


3. Kurth AH, Kim SZ, Sedlmeyer I, Hovy L, Bauss F: Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br; 2000 Jan;82(1):126-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with ibandronate preserves bone in experimental tumour-induced bone loss.
  • The third-generation bisphosphonate, ibandronate (BM 21.0955), is a potent compound for controlling tumour osteolysis and hypercalcaemia in rats bearing Walker 256 carcinosarcoma.
  • We have studied the effect of ibandronate given as an interventional treatment on bone strength and bone loss after the onset of tumour growth in bone.
  • Our results suggest that it is capable of preserving bone quality in rats bearing Walker 256 carcinosarcoma cells.
  • Since other bisphosphonates have produced comparable results in man after their success in the Walker 256 animal models our findings suggest that ibandronate may be a powerful treatment for maintaining skeletal integrity in patients with metastatic bone disease.
  • [MeSH-major] Bone Resorption / drug therapy. Carcinoma 256, Walker / complications. Diphosphonates / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10697328.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


Advertisement
4. Welchinskaya HV, Piecuszak B, Kovalenko EA, Sharykina NI, Getman KI, Podgorsky VS: Biological activity of bacterial lectins and their molecular complexes with heterocyclic bis-adducts. Mikrobiol Z; 2003 Sep-Oct;65(5):20-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was discovered that these substances apply to a few toxic preparations and have a expression antitumour action on the tumours: Walker carcinosarcoma 256, Pliss' lymphosarcoma and Sarcoma 45.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Heterocyclic Compounds / chemistry. Lectins / chemistry. Lectins / therapeutic use. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Bacillus / chemistry. Benzimidazoles / chemistry. Carcinoma 256, Walker / drug therapy. Crown Ethers. Halothane / chemistry. Imidazoles / chemistry. Lethal Dose 50. Lymphoma, Non-Hodgkin / drug therapy. Mice. Rats. Sarcoma, Experimental / drug therapy. Uracil / chemistry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE .
  • Hazardous Substances Data Bank. BENZIMIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723158.001).
  • [ISSN] 1028-0987
  • [Journal-full-title] Mikrobiolohichnyĭ zhurnal (Kiev, Ukraine : 1993)
  • [ISO-abbreviation] Mikrobiol. Z.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Crown Ethers; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Lectins; 56HH86ZVCT / Uracil; 63J177NC5B / 18-crown-6; 7GBN705NH1 / imidazole; E24GX49LD8 / benzimidazole; UQT9G45D1P / Halothane
  •  go-up   go-down


5. Sasajima T, Shimada N, Naitoh Y, Takahashi M, Hu Y, Satoh T, Mizoi K: (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int J Cancer; 2007 Dec 15;121(12):2637-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
  • Malignant tumor cells (RG2 and C6 gliomas, Walker 256 carcinoma) were incubated with low dose vincristine (VCR) to induce multidrug resistance.
  • MTT assay demonstrated a significant increase of surviving fractions in VCR-resistant sublines compared to those of drug-naive cells.
  • Reverse transcriptase polymerase chain reaction revealed higher expression of MDR1 mRNA in VCR-resistant cells than drug-naive cells in each line.
  • Volume distribution (V(d)) of (99m)Tc-MIBI was negatively correlated with MDR1 mRNA expression among drug-naive and VCR-resistant cells.
  • Autoradiographic images of (99m)Tc-MIBI revealed higher uptake in drug-naive cells at basal ganglia compared with VCR-resistant cells at the opposite basal ganglia of rats.
  • Therapeutic effects of VCR with or without the MDR1 inhibitors were also evaluated autoradiographically using (14)C-methyl-L-methionine ((14)C-Met) and MIB-5 index. (14)C-Met uptake and MIB-5 index of both tumors treated with VCR following the MDR1 inhibitor treatment significantly decreased compared with tumors treated with VCR alone.
  • Analysis of (99m)Tc-MIBI accumulation is considered informative for detecting MDR1-mediated drug resistance and for monitoring the therapeutic effects of MDR1 inhibitors in malignant brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / radionuclide imaging. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / radionuclide imaging. P-Glycoprotein / antagonists & inhibitors. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Animals. Autoradiography. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclosporine / pharmacology. Cyclosporins / pharmacology. Cytotoxins / pharmacology. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Drug Synergism. Predictive Value of Tests. Quinolines / pharmacology. RNA, Messenger / metabolism. Radiopharmaceuticals. Rats. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17708555.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / Cytotoxins; 0 / P-Glycoprotein; 0 / Quinolines; 0 / RNA, Messenger; 0 / Radiopharmaceuticals; 0BJK6B565B / dofequidar; 121584-18-7 / valspodar; 5J49Q6B70F / Vincristine; 83HN0GTJ6D / Cyclosporine; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


6. Gade TP, Spees WM, Le HC, Zakian KL, Ponomarev V, Doubrovin M, Gelovani JG, Koutcher JA: In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method. Magn Reson Med; 2004 Jul;52(1):169-73
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 5-fluorouracil and fluoronucleotide T1 relaxation time measurements using the variable nutation angle method.
  • 19Fluorine NMRS has the potential to enable noninvasive predictions of tumor response to 5-fluorouracil (5FU) therapy based on tumor pharmacokinetics.
  • We used the variable nutation angle (VNA) method to determine T1's of 5FU and FNuc in subcutaneous Walker 256 rat mammary carcinosarcoma tumors transfected with a cytosine deaminase/uracil phosphoribosyltransferase fusion gene.
  • [MeSH-major] Fluorouracil / metabolism. Magnetic Resonance Spectroscopy / methods. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15236381.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA86438; United States / NCI NIH HHS / CA / R01CA8314; United States / NCI NIH HHS / CA / R24CA83084
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Wu HP, Feng GS, Tian Y: Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats. World J Gastroenterol; 2005 Apr 28;11(16):2408-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the distribution and stability of antisense oligodeoxynucleotide (ASODN) in Walker-256 cells and their distribution in liver, lung and kidney tissues after being infused alone or mixed with lipiodol via hepatic artery in a rat liver tumor model.
  • METHODS: 5'-Isothiocyanate (FITC)-labeled vascular endothelial growth factor (VEGF) ASODN was added into Walker-256 cell culture media.
  • Its distribution in cells was observed by fluorescence microscope at different time points.
  • Walker-256 carcinosarcoma was transplanted into Wistar rat liver to establish a liver cancer model.
  • Frozen samples of liver, lung and kidney tissue were taken from rats after 1, 3 and 6 d, respectively.
  • In mixed group, ASODN was mainly distributed in liver tumor tissues.
  • CONCLUSION: ASODN can transfect Walker-256 cells.
  • ASODN mixed with lipiodol infusion via hepatic artery can be used in the treatment of HCC.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Contrast Media / pharmacokinetics. Iodized Oil / pharmacokinetics. Liver Neoplasms / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Fluorescein-5-isothiocyanate / pharmacokinetics. Fluorescent Dyes / pharmacokinetics. Hepatic Artery. Male. Neoplasm Transplantation. Rats. Rats, Wistar. Specific Pathogen-Free Organisms. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832409.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Oligodeoxyribonucleotides, Antisense; 0 / Vascular Endothelial Growth Factor A; 8001-40-9 / Iodized Oil; I223NX31W9 / Fluorescein-5-isothiocyanate
  • [Other-IDs] NLM/ PMC4305626
  •  go-up   go-down


8. Su M, Qiu Y, Jia W: A pilot study of antitumor effect of gallium ethylenediaminetetramethylene phosphonate [Ga(III)-EDTMP] in tumor-bearing rats. Adv Ther; 2005 Jul-Aug;22(4):297-306
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibitory effects of gallium ethylenediamine-N,N,N',N'-tetrakismethylene phosphonate [Ga(III)-EDTMP] was studied on a malignant tumor and metastatic bone lesion model induced with Walker carcinosarcoma 256 (WCS 256) in Wistar rats weighing 120 to 135 g.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Chelating Agents / therapeutic use. Gallium / therapeutic use. Organophosphorus Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418139.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chelating Agents; 0 / Organophosphorus Compounds; 1429-50-1 / (ethylenedinitrilo)-tetramethylenephosphonic acid; CH46OC8YV4 / Gallium
  •  go-up   go-down


9. Ovsjanko EV, Lushnikova EL, Larionov PM, Arkhipov SA, Nepomnyashchikh LM, Efremov AV, Ovsjanko YU: Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs. Bull Exp Biol Med; 2009 Oct;148(4):650-5
Hazardous Substances Data Bank. MELATONIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study for the expression of Bcl-2 family proteins in Walker 256 carcinosarcoma cells under the influence of cytostatic drugs.
  • Immunohistochemical study was performed to evaluate the expression of Bcl-2 family proteins (Bcl-2, Bax, and Bad) in Walker 256 carcinosarcoma cells after implantation into the thigh muscle of male Wistar rats (10(6) cells).
  • The experiment was conducted under conditions of spontaneous tumor development and individual or combined treatment with melatonin and cyclophosphamide.
  • The use of melatonin as monotherapy or in combination with cyclophosphamide was followed by a significant decrease in Bcl-2 expression in carcinosarcoma cells.
  • The Bcl-2/Bax and Bcl-2/Bad ratio was significantly reduced under these conditions (particularly after combined treatment with cytostatic drugs).
  • Daily treatment with melatonin was accompanied by significant changes in the structure of Walker 256 carcinosarcoma.
  • It was manifested in the formation of connective tissue septa and pseudofollicles.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Cytostatic Agents / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Antioxidants / therapeutic use. Cyclophosphamide / therapeutic use. Humans. Male. Melatonin / therapeutic use. Neoplasm Transplantation. Rats. Rats, Wistar. Tumor Cells, Cultured. bcl-2-Associated X Protein / metabolism. bcl-Associated Death Protein / metabolism

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396763.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antioxidants; 0 / Cytostatic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0 / bcl-Associated Death Protein; 8N3DW7272P / Cyclophosphamide; JL5DK93RCL / Melatonin
  •  go-up   go-down


10. Dima VF, Ionescu MD: Ultrastructural changes induced in Walker carcinosarcoma by treatment with dihematoporphyrin ester and light in animals with diabetes mellitus. Roum Arch Microbiol Immunol; 2000 Jan-Jun;59(1-2):119-30
Hazardous Substances Data Bank. ALLOXAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrastructural changes induced in Walker carcinosarcoma by treatment with dihematoporphyrin ester and light in animals with diabetes mellitus.
  • The purpose of this study was to evaluate by electron microscopy the tumoral fine structure changes induced by photodynamic therapy (PDT) in diabetic animals.
  • Walker -256 carcinosarcoma harvested from animals with/without diabetes mellitus exposed to PDT (Photofrin II/5 mg/kg and 24 hrs later He-Ne laser irradiation/632.8 nm; 10 mW) and examined by electron microscopy showed different degrees of lesions in the nucleus and cytoplasmic fine structure.
  • The ultrastructural changes induced by PDT in animals with diabetes mellitus bearing carcinosarcoma are characterized by: lysis of chromatin situated on the central zone of nucleus; swelling and vacuolization of mitochondria; formation of phagosome--like structures; myelin figures; degenerescence and disappearance of cytoplasmic organelles.
  • Summing up, the data presented in this work demonstrate that the exposure to three doses of PDT produces changes in tumoral fine structure, increases survival rate and reduces incidence of carcinosarcoma in rats with diabetes mellitus.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Diabetes Mellitus, Experimental / complications. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11845470.001).
  • [ISSN] 1222-3891
  • [Journal-full-title] Roumanian archives of microbiology and immunology
  • [ISO-abbreviation] Roum Arch Microbiol Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6SW5YHA5NG / Alloxan; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


11. Plotnikov MB, Maslov MIu, Aliev OI, Vasil'ev AS, Zueva EP, Krylova SG, Shilova NV: [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats]. Vopr Onkol; 2001;47(3):335-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disorders of blood rheology in Walker's carcinosarcoma-256 and in cyclophosphamide treatment of rats].
  • [Transliterated title] Narusheniia reologicheskikh svoĭstv krovi u krys s kartsinosarkomoĭ 256 Walker i pri khimioterapii tsiklofosfanom.
  • Tumor process development in rats inoculated with cellular suspension of transplantable Walker's carcinosarcoma-256 involved enhanced thickening of blood on day 7.
  • Treatment with 20 mg/kg cyclophosphamide, thrice a day, every other day, retarded tumor process and brought hemorheologic indices further down, at the same time.
  • Similar treatment of intact rats with cyclophosphamide caused hemorheologic disorders too.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Cyclophosphamide / pharmacology. Hemorheology / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11544834.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Kolganov AS: [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia]. Vopr Onkol; 2001;47(1):81-5
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental chemotherapy of malignant tumors in combination with short-term general hypoxia].
  • [Transliterated title] Eksperimental'naia khimioterapiia zlokachestvennykh opukholeĭ v sochetanii s kratkovremennoĭ obshcheĭ gipoksieĭ.
  • The effect of hypoxy on chemotherapy with emoxyl, 5-fluorouracil and bleomycin which are characterized by different affinities with oxygen has been investigated.
  • In an experiment using 96 rats, each weighing 180 g, subcutaneously inoculated with Walker's carcinosarcoma and carcinoma.
  • PC-1, combined use of chemotherapy and hypoxy was followed by a significant inhibition of tumor growth rate, against a background of significant drop in survival due to the increased toxic effect of the drugs.
  • Therefore, hypoxy cannot be recommended for modifying chemotherapy of tumors irrespective of drug affinity with oxygen.
  • [MeSH-major] Anoxia. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Carcinoma 256, Walker / therapy. Daunorubicin / analogs & derivatives. Daunorubicin / therapeutic use

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317544.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 84412-94-2 / Emoxyl; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


13. Zalietok SP, Orlovs'kyĭ OA, Hohol' SV, Samoĭlenko OA, Hulua L, Kvesitadze HI: [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats]. Lik Sprava; 2006 Dec;(8):89-93
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of plant biocomposites based on Georgian tea "per se" and in combination with cisplatin on Walker carcinosarcoma W-256 and Guerin's carcinoma growth rate in rats].
  • Green tea biocomposite had effectivey hampered the growth of rat Walker W-256 carcinoma and in less extent rat Guerin's carcinoma.
  • Black tea biocomposite had not practically influenced on Guerin's carcinoma growth.
  • The biocomposite from green tea and extract from red vine rind and lemon suppressed at the level of tendency the growth of rat Walker W-256 carcinoma.
  • The biocomposite from green tea and extract from red vine rind had hampered only Guerin's carcinoma growth and at the tendency had increased the growth of W-256 carcinosarcoma growth.
  • This biocomposite increased also considerably the therapeutic efficiency of cisplatin on Guerin's carcinoma.

  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427433.001).
  • [ISSN] 1019-5297
  • [Journal-full-title] Likars'ka sprava
  • [ISO-abbreviation] Lik. Sprava
  • [Language] UKR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Nogusa H, Yamamoto K, Yano T, Kajiki M, Hamana H, Okuno S: Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents. Biol Pharm Bull; 2000 May;23(5):621-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma and tissue distribution of conjugates of carboxymethylpullulan (CMPul) and doxorubicin (DXR), either bound directly or through three types of tetrapeptide spacers, was studied after intravenous injection to rats bearing Walker 256 carcinosarcoma and compared with that of DXR.
  • Disposition characteristics of [3H]CMPul in rats bearing Walker 256 carcinosarcoma indicate that pullulan, which had molecular weight over 50 kDa, is a suitable macromolecular carrier for tumor targeting in cancer chemotherapy by carboxymethylation.
  • CMPul-DXR conjugates were also distributed in the reticuloendothelial organs, such as liver, spleen and bone marrow; however, the tissue concentrations of the conjugates in the heart, lung and muscle were lower than those of DXR.
  • We next investigated the effect of the DXR contents of CMPul-DXR conjugates on their body distribution in rats bearing Walker 256.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinosarcoma / metabolism. Doxorubicin / pharmacokinetics. Glucans / pharmacokinetics
  • [MeSH-minor] Animals. Carbohydrate Sequence. Female. Male. Mice. Molecular Sequence Data. Peptides / administration & dosage. Peptides / chemistry. Rats. Rats, Wistar. Tissue Distribution. Tritium

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10823676.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucans; 0 / Peptides; 0 / carboxymethylpullulan; 10028-17-8 / Tritium; 80168379AG / Doxorubicin
  •  go-up   go-down


15. Tandon VK, Yadav DB, Chaturvedi AK, Shukla PK: Synthesis of (1,4)-naphthoquinono-[3,2-c]-1H-pyrazoles and their (1,4)-naphthohydroquinone derivatives as antifungal, antibacterial, and anticancer agents. Bioorg Med Chem Lett; 2005 Jul 1;15(13):3288-91
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The structure-activity relationship of these compounds was studied and the results show that the compound 2b exhibited in vitro antifungal activity against Candida albicans and Cryptococcus neoformans, and also possessed antibacterial profile against Klebsiella pneumoniae and Escherichia coli whereas 1c showed anticancer activity against Walker 256 Carcinosarcoma in rats.
  • [MeSH-minor] Animals. Candida albicans / drug effects. Carcinoma 256, Walker / drug therapy. Cryptococcus neoformans / drug effects. Escherichia coli / drug effects. Klebsiella pneumoniae / drug effects. Microbial Sensitivity Tests. Naphthoquinones / pharmacology. Rats. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913995.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Naphthoquinones; 0 / Pyrazoles
  •  go-up   go-down


16. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical trial of the antitumoral therapeutic effectiveness of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):105-18
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical trial of the antitumoral therapeutic effectiveness of some natural polyphenolic biopreparations.
  • We studied the therapeutic effect of different doses on the tumor generation process and compared it with the experimental oncostatic action of several standard chemotherapeutic drugs of clinical use (thiotepa, methotrexate, melphalan and cyclophosphamide).
  • In our experimental treatment with the bioactive polyphenolic agents, we have used various doses, both higher and lower than the dose that had conditioned the expression of their antitumoral action upon Guerin T-8 lymphotropic epithelioma and upon Walker 256 carcinosarcoma.
  • We compared the evaluation indices of the antitumoral pharmacodynamic effect we obtained in the treatment with the POLYAS biopreparations with those of reference cytostatic agents.
  • Antitumoral effectiveness can be improved by an experimental manipulation of the therapeutic doses--which proves the existence of a dose-response relationship.
  • The quantitative preclinical evaluation of the specific pharmacodynamic effect will be complemented by the investigation of the new polyphenolic biopreparations therapeutic effectiveness in tumors with various degrees of development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413151.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


17. Rotinberg P, Kelemen S, Gramescu M, Rotinberg H, Nuta V: Preclinical qualitative evaluation of the antitumoral pharmacodynamic action of some natural polyphenolic biopreparations. Rom J Physiol; 2000 Jan-Dec;37(1-4):91-103
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of in vivo tests of their effect on the development of Guerin T-8 lymphotropic epithelioma and Walker 256 carcinosarcoma were conducted.
  • All those results highlighted the antineoplastic pharmacotherapeutic effect of the polyphenolic biopreparations and also proved that effect to be replicable.
  • The qualitative evaluation of the pharmacodynamic action of those preparations was a condition for their further quantitative pharmacological evaluation in point of antitumoral therapeutic effectiveness in a preclinical stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413150.001).
  • [ISSN] 1223-4974
  • [Journal-full-title] Romanian journal of physiology : physiological sciences
  • [ISO-abbreviation] Rom J Physiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polymers; 0 / Polyphenols
  •  go-up   go-down


18. Dubin M, Fernandez Villamil SH, Stoppani AO: [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires); 2001;61(3):343-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
  • [Transliterated title] Citotoxicidad de la beta-lapachona: una o-naftoquinona con posibles usos terapéuticos.
  • Initial observations proved its capability for inhibiting growth of Yoshida tumor and Walker 256 carcinosarcoma. beta-Lap redox-cycling in the presence of reductants and oxygen yields "reactive oxygen species" (ROS: O2-, OH and H2O2) which cytotoxicity led to assume its role in beta-lap activity in cells. beta-Lap inhibited DNA synthesis in Trypanosoma cruzi as well as topoisomerases I and II, poly(ADP-ribose) polymerase (PARP) in different cells.
  • These enzymes are essential for maintaining DNA structure. beta-Lap inhibited growth of a large variety of tumor cells including epidermoid laringeal cancer, prostate, colon, ovary and breast cancer and also different types of leukemia cells.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Naphthoquinones / pharmacology. Neoplasms / drug therapy. Poly(ADP-ribose) Polymerases / metabolism. Reactive Oxygen Species / physiology
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / enzymology. Humans. Sarcoma, Yoshida / drug therapy. Sarcoma, Yoshida / enzymology. Topoisomerase I Inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11474885.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Naphthoquinones; 0 / Reactive Oxygen Species; 0 / Topoisomerase I Inhibitors; 4707-32-8 / beta-lapachone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 58
  •  go-up   go-down


19. Clichici S, Filip A, Daicoviciu D, Ion RM, Mocan T, Tatomir C, Rogojan L, Olteanu D, Muresan A: The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin. Acta Physiol Hung; 2010 Mar;97(1):41-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dynamics of reactive oxygen species in photodynamic therapy with tetra sulfophenyl-porphyrin.
  • Photodynamic therapy (PDT) is a promising therapy especially in skin cancer, using the systemic administration of a photosensitizer (PS), followed by the local irradiation of the tumor with visible light.
  • Our study evaluates the effects of PDT with TSPP upon the tumor levels of ROS and upon the metalloproteinases 2 (MMP2) activities on Wistar male rats bearing 256 Walker carcinosarcoma in correlation with the accumulation of PS in the tumor and with the intratumor histological alterations.
  • Our results emphasize that 24 hours after the PDT with TSPP, the ROS generation increases, as revealed by protein carbonyls and malondialdehyde levels and the antioxidant capacity (hydrogen donors, thiol groups) decreases in the tumor tissue.
  • [MeSH-major] Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / metabolism. Photochemotherapy. Porphyrins / therapeutic use. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Animals. Antioxidants / metabolism. Kinetics. Male. Matrix Metalloproteinase 2 / metabolism. Oxidative Stress / drug effects. Photosensitizing Agents / pharmacology. Photosensitizing Agents / therapeutic use. Rats. Rats, Wistar. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233689.001).
  • [ISSN] 0231-424X
  • [Journal-full-title] Acta physiologica Hungarica
  • [ISO-abbreviation] Acta Physiol Hung
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Photosensitizing Agents; 0 / Porphyrins; 0 / Reactive Oxygen Species; 35218-75-8 / tetraphenylporphine sulfonate; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


20. Dowell JA, Sancho AR, Anand D, Wolf W: Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Adv Drug Deliv Rev; 2000 Mar 15;41(1):111-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors.
  • An effective methodology to determine the amount of cisplatin or carboplatin at the solid tumor site in a noninvasive manner may enable clinicians to design drug regimens based on an individual's in situ pharmacokinetics.
  • Such noninvasive methods may allow optimization of an individual's drug exposure at the target site, as well as provide a screening measure to determine individual efficacy based on exposure to these platinated drugs.
  • 195mPt appears to be the radionuclide of platinum most suitable for radiolabeling cisplatin or carboplatin, and an analysis is presented of the methods available for preparing such radiolabeled drugs.
  • The animals used were Sprague Dawley rats bearing the Walker 256 carcinoma, and drug biodistribution was studied following administration of cisplatin or carboplatin radiolabeled with 195mPt.
  • This radionuclide permitted noninvasive imaging of the drug and its metabolites at the tumor site and at selected organs.
  • The results obtained show an ability to estimate the amount of platinated drug species in the tumor environment using a noninvasive methodology.
  • This noninvasive method is able to provide individual estimates of the active component of the drug at the target site, and is therefore a method that can be implemented in human studies.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Neoplasms / drug therapy. Organoplatinum Compounds / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10699308.001).
  • [ISSN] 0169-409X
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 38
  •  go-up   go-down


21. Paterson AH: The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer; 2000 Jun 15;88(12 Suppl):3038-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
  • Within the family of BPs there are more similarities in pharmacologic effects than differences, although side effect profiles, rates of oral absorption, and potency do differ.
  • Oral clodronate and intravenous pamidronate reduce skeletal complications in patients with bone metastases from breast carcinoma (as well as in myeloma).
  • Uncontrolled trials of prostate carcinoma also suggest clinical benefit.
  • METHODS: Animal studies show that BPs can reduce the rate of development of bone metastases (for example, in Walker 256 carcinoma), but there is little evidence of an effect at nonosseous sites.
  • RESULTS: In patients with recurrent breast carcinoma but no overt bone metastases, oral clodronate reduced the number of diagnosed bone metastases; but the number of patients who had relapses in bone, though smaller, was not significantly different from the number among patients who took placebo.
  • Patients treated for operable breast carcinoma have four or five times the normal rate of vertebral fracture, and BPs do reduce the rate of bone loss.
  • ), showed a reduction in osseous and nonosseous recurrences and an increase in disease free and overall survival with 2 years of clodronate.
  • A second open-label trial (Saarto et al.) of similar size involving lymph node positive breast carcinoma patients showed no effect on the rate of bone metastasis relapse and a deleterious effect on relapse rates of nonosseous metastases with 3 years of clodronate.
  • A third placebo-controlled trial involving 1079 patients reported, in an interim analysis, a reduction in osseous metastases during treatment with 2 years of clodronate, but no effect on nonosseous metastases or survival.
  • 1) scientifically, it is important to demonstrate that an agent that has its dominant effect on a normal tissue cell, the osteoclast, can influence the growth of neoplastic cells; and 2) from the perspective of patient care, it must be unequivocally shown that a reduction in the rate of osseous recurrence translates into an improvement in disease free survival or an improvement in quality of life through reduction of adverse skeletal events.
  • The National Surgical Adjuvant Breast Project has committed to conducting this study and including women with operable breast carcinoma.
  • [MeSH-major] Bone Neoplasms / prevention & control. Bone Neoplasms / secondary. Diphosphonates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Clinical Trials as Topic. Female. Humans. Spinal Fractures / etiology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898349.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 62
  •  go-up   go-down


22. Stepensky D, Golomb G, Hoffman A: Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci; 2002 Feb;91(2):508-16
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two rat models of bone disease were applied.
  • Bone cancer was produced by intratibial inoculation of Walker carcinosarcoma cells, and a model of augmented bone resorption was produced by vitamin D(3) treatment of rats that had undergone thyroidparathyroidectomy.
  • Higher amounts of alendronate were found in bones and in internal organs after bolus drug administration as compared with continuous infusion.
  • Drug effects on plasma calcium levels and on urine calcium excretion were similar in both modes of alendronate administration.
  • [MeSH-minor] Animals. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / urine. Bone Resorption / drug therapy. Calcium / blood. Calcium / urine. Carcinoma 256, Walker / blood. Carcinoma 256, Walker / drug therapy. Carcinoma 256, Walker / pathology. Carcinoma 256, Walker / urine. Drug Administration Schedule. Drug Evaluation, Preclinical / methods. Female. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / urine. Male. Neoplasm Transplantation. Parathyroidectomy. Rats. Rats, Sprague-Dawley. Rats, Wistar. Thyroidectomy. Tibia / pathology

  • Hazardous Substances Data Bank. Alendronic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:508-516, 2002
  • (PMID = 11835209.001).
  • [ISSN] 0022-3549
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


23. Kurth AA, Kim SZ, Shea M, Bauss F, Hayes WC, Müller R: Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis. J Bone Miner Metab; 2007;25(2):86-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
  • Walker carcinosarcoma cells were implanted into the left femur of female rats that received 26-day ibandronate pretreatment followed by continued therapy or ibandronate posttreatment only.
  • At endpoint, excised femurs were scanned using microcomputed tomography (microCT) to assess bone volume density, bone mineral content, trabecular number/thickness, and separation for cortical plus trabecular bone or trabecular bone alone.
  • Compared with the nonimplanted right femur, bone volume and surface density and trabecular number and thickness were reduced in the distal left femur following tumor cell implantation. microCT analysis revealed greater cortical and trabecular bone mineral content in the preventative and interventional (pre-post tumor) ibandronate group, and the interventional (post-tumor) ibandronate group, versus the tumor-only group.
  • After preventative and interventional ibandronate, bone volume density and trabecular thickness were 13% and 60% greater, respectively, than in the post-tumor treatment group.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone and Bones / pathology. Carcinoma 256, Walker / pathology. Diphosphonates / therapeutic use
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Femur / drug effects. Femur / pathology. Image Processing, Computer-Assisted. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 May 15;99(10 ):2509-17 [9153295.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17 (7):1139-47 [12096826.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5452-7 [8221685.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 May;20(5):685-93 [6428894.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3890-4 [9307266.001]
  • [Cites] Phys Med Biol. 1994 Jan;39(1):145-64 [7651993.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3219-24 [12149294.001]
  • [Cites] Br J Haematol. 1997 Sep;98(3):665-72 [9332325.001]
  • [Cites] Endocrinology. 1996 Jun;137(6):2324-33 [8641182.001]
  • [Cites] N Engl J Med. 1998 Aug 6;339(6):357-63 [9691101.001]
  • [Cites] J Bone Miner Res. 1994 Feb;9(2):221-30 [8140935.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):698-705 [8698861.001]
  • [Cites] Anat Rec. 1997 Dec;249(4):458-68 [9415453.001]
  • [Cites] Osteoporos Int. 2001;12 (11):936-41 [11804020.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):126-30 [10697328.001]
  • [Cites] Bone. 2004 Apr;34(4):736-46 [15050906.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3080-8 [10898355.001]
  • [Cites] Osteoporos Int. 2004 Jun;15(6):423-33 [15205712.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4418-24 [11389070.001]
  • [Cites] Bone. 2002 Jan;30(1):300-6 [11792601.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):1932-41 [14606504.001]
  • [Cites] J Bone Miner Res. 1995 Oct;10(10):1478-87 [8686503.001]
  • [Cites] Osteoporos Int. 1998;8(2):97-103 [9666930.001]
  • [Cites] Calcif Tissue Int. 1996 Jan;58(1):24-9 [8825235.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):91-8 [8508433.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:453-65 [10415748.001]
  • [Cites] Mol Pharmacol. 1996 Nov;50(5):1127-38 [8913344.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1482-91 [8889848.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):468-77 [14506749.001]
  • [Cites] Osteoporos Int. 2002 Oct;13(10):816-23 [12378371.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1167-74 [10404017.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3551-7 [7627963.001]
  • [Cites] Cancer Res. 1984 Jul;44(7):3007-11 [6233002.001]
  • [Cites] J Cancer Res Clin Oncol. 1987;113(6):539-43 [3119600.001]
  • [Cites] J Orthop Res. 2001 Mar;19(2):200-5 [11347691.001]
  • [Cites] J Cancer Res Clin Oncol. 1986;111(1):35-41 [3949849.001]
  • [Cites] Drugs. 2000 Mar;59(3):391-9 [10776826.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] Oncology. 1988;45(1):41-6 [3340393.001]
  • [Cites] J Bone Miner Res. 2004 Nov;19(11):1787-96 [15476578.001]
  • (PMID = 17323177.001).
  • [ISSN] 0914-8779
  • [Journal-full-title] Journal of bone and mineral metabolism
  • [ISO-abbreviation] J. Bone Miner. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; UMD7G2653W / ibandronic acid
  •  go-up   go-down


24. Silva SL, Silva SF, Cavalcante RO, Mota RS, Carvalho RA, Moraes MO, Campos HH, Moraes ME: Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc; 2004 May;36(4):1004-6
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine.
  • PURPOSE: To investigate the effect of mycophenolate mofetil on Walker's carcinosarcoma, without versus with the growth and regression of cyclosporine.
  • CONCLUSIONS: MMF produces an anti-tumoral effect against Walker's carcinosarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma 256, Walker / drug therapy. Mycophenolic Acid / analogs & derivatives. Mycophenolic Acid / therapeutic use
  • [MeSH-minor] Animals. Cell Division / drug effects. Cyclosporine / therapeutic use. Male. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15194349.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 83HN0GTJ6D / Cyclosporine; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


25. Sugahara S, Okuno S, Yano T, Hamana H, Inoue K: Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol Pharm Bull; 2001 May;24(5):535-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting.
  • Using the Walker 256 model for carcinosarcoma-bearing rats, we intravenously administered 5 polysaccharide carriers with various molecular weights (MWs) and electric charges and tested for their plasma and tissue distribution.
  • As for the anionic charge, CMDex (110-180 kDa) with a degree of substitution (DS) of the CM groups ranging from 0.2 to 0.6, showed maximum plasma AUC values.
  • Doxorubicin (DXR) was bound to these carriers via a peptide spacer, GlyGlyPheGly (GGFG), to give carrier-GGFG-DXR conjugates (DXR content: 4.2-7.0 (w/w)%), and the antitumor effects of these conjugates were tested with Walker 256 carcinosarcoma-bearing rats by monitoring the tumor weights after a single intravenous injection.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers. Polysaccharides / pharmacokinetics
  • [MeSH-minor] Animals. Carcinoma 256, Walker / drug therapy. Doxorubicin / administration & dosage. Female. Molecular Weight. Rats. Rats, Wistar. Tissue Distribution

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11379776.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Polysaccharides; 80168379AG / Doxorubicin
  •  go-up   go-down


26. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J: Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv; 2009 Jul;6(3):255-60
Hazardous Substances Data Bank. Sulfur, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Success of selective drug therapies depends on the drug's depot time in the target to treat.
  • Depot time is currently being prolonged, using drug-eluting beads or microspheres for selective internal radiation therapy.
  • The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size.
  • MATERIALS AND METHODS: An animal model with two different vascularized tumors (Walker Carcinoma 256 (hypervascularized) and Yoshida Sarcoma (hypovascularized)) was used.
  • Tumor activity was measured with a gamma camera at 10 min, 1h, 3h, 6h, 14h and 48h p.i.
  • Measurements were adjusted for decay times and then compared.
  • CONCLUSIONS: Particle stay time, biodistribution, and stability can be easily monitored as shown in this animal model.
  • Prolonged retention is independent of vascularization and particle size and appears to be sufficient for therapy.
  • [MeSH-minor] Animals. Carcinoma 256, Walker / blood supply. Carcinoma 256, Walker / metabolism. Epinephrine / pharmacology. Female. Humans. Injections, Intralesional. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Radioisotopes / chemistry. Rats. Rats, Wistar. Rhenium / chemistry. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / metabolism. Serum Albumin / chemistry. Spleen / metabolism. Sulfur / chemistry. Tissue Distribution / drug effects

  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604139.001).
  • [ISSN] 1567-2018
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0 / rhenium sulfur colloid; 70FD1KFU70 / Sulfur; 7440-15-5 / Rhenium; YKH834O4BH / Epinephrine
  •  go-up   go-down


27. Kurth AA, Kim SZ, Sedlmeyer I, Bauss F, Shea M: Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone; 2002 Jan;30(1):300-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
  • Bisphosphonate treatment is beneficial against symptoms of metastatic bone disease, although less is known about the effect of preventative treatment schedules.
  • We investigated the effect of various treatment regimens of the bisphosphonate, ibandronate (IB), on the preservation of bone quality in a rat model of tumor-induced osteolysis.
  • Osteolytic Walker 256 (W256) carcinosarcoma cells were implanted into the left femur of female Sprague-Dawley rats, resulting in a 10% reduction in bone mineral density (BMD), a 16% reduction in bone density (BD), and a 26% reduction in failure load compared with the right femur 28 days after implantation.
  • IB was administered subcutaneously in five different treatment schedules:.
  • (2) IB PRE-POST SHAM received the same IB administration, but with a sham operation;.
  • (4) IB PRE-0 received IB injections for 26 days and was then killed to serve as a time zero control; and (5) IB POST received sham injection with saline before W256 cell insertion, and then received IB injections for 28 days until killing.
  • We used dual-energy X-ray absorptiometry (DXA) to measure distal femur BMD and bone mineral content (BMC), peripheral quantitative computed tomography (pQCT) to measure distal femur BD, and torsion testing to obtain torsional failure load.
  • Combined preventative and interventional IB treatment best preserved bone mass and strength, although all treatment schedules resulted in significant improvement compared with untreated controls (TUMOR ONLY).
  • The possibility of reducing or even preventing skeletal morbidity in cancer patients with a high risk of developing metastatic spreading to bone is exciting, and warrants further exploration.
  • [MeSH-major] Bone Density / drug effects. Bone Neoplasms / drug therapy. Bone Neoplasms / physiopathology. Diphosphonates / therapeutic use. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / physiopathology
  • [MeSH-minor] Animals. Biomechanical Phenomena. Female. Fractures, Bone / prevention & control. Humans. Mammary Neoplasms, Experimental / complications. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / physiopathology. Osteolysis / drug therapy. Osteolysis / etiology. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11792601.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 114084-78-5 / ibandronic acid
  •  go-up   go-down


28. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K: Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res; 2000 Jun 1;60(11):2988-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To improve their pharmacological profiles, a new macromolecular prodrug, denoted T-0128, was synthesized.
  • This prodrug is a novel CPT analogue (T-2513)-carboxymethyl (CM) dextran conjugate via a triglycine spacer, with a molecular weight of Mr 130,000.
  • This study was designed to test the concept that the rational design of a CPT-polymer conjugate would increase the efficacy of the parent drug.
  • The in vivo antitumor study against Walker-256 carcinoma demonstrated that T-0128 was 10 times as active as T-2513, supporting this concept.
  • Even a single i.v. injection of T-0128 at 6 mg/kg (based on the amount of T-2513 bound to CM dextran) induced complete regression of MX-1 mammary carcinoma.
  • T-0128 at 10 mg/kg weekly for 3 weeks (one-tenth of its MTD) cured LX-1 lung carcinoma.
  • These demonstrate the broad range of therapeutic doses achieved with T-0128.
  • Pharmacokinetic studies were performed to correlate the efficacy results obtained for T-0128 with plasma and tissue drug concentrations using Walker-256 tumor-bearing rats.
  • The significant increases in the amount and exposure time of released T-2513 in the tumor explain well the enhanced efficacy of T-0128.
  • [MeSH-major] Breast Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Dextrans / pharmacology. Lung Neoplasms / drug therapy. Prodrugs / pharmacology. Topotecan / analogs & derivatives
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Chromatography, Gel. Chromatography, High Pressure Liquid. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Female. HeLa Cells. Humans. Male. Mice. Mice, Nude. Neoplasm Transplantation. Rats. Rats, Wistar. Time Factors. Tissue Distribution. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10850447.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Prodrugs; 0 / T 0128; 0 / T 2153; 7M7YKX2N15 / Topotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; K3R6ZDH4DU / Dextrans; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


29. Bastos-Pereira AL, Lugarini D, Oliveira-Christoff Ad, Ávila TV, Teixeira S, Pires Ado R, Muscará MN, Cadena SM, Donatti L, Cristina da Silva de Assis H, Acco A: Celecoxib prevents tumor growth in an animal model by a COX-2 independent mechanism. Cancer Chemother Pharmacol; 2010 Jan;65(2):267-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Nonsteroidal antiinflammatory drugs (NSAIDs) have been shown to reduce cell growth in several tumors.
  • Among these possible antineoplastic drugs are cyclooxygenase- 2 (COX-2)-selective drugs, such as celecoxib, in which antitumoral mechanisms were evaluated in rats bearing Walker-256 (W256) tumor.
  • METHODS: W256 carcinosarcoma cells were inoculated subcutaneously (10(7) cells/rat) in rats submitted to treatment with celecoxib (25 mg kg(-1)) or vehicle for 14 days.
  • CONCLUSION: These results confirm the antitumor effects of celecoxib in W256 cancer model, contributing to elucidating its antitumoral mechanism and corroborating scientific literature about its effect on other types of cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclooxygenase 2 / physiology. Cyclooxygenase 2 Inhibitors / therapeutic use. Neoplasms, Experimental / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Body Weight / drug effects. Catalase / metabolism. Celecoxib. Free Radical Scavengers / pharmacology. Glutathione Transferase / metabolism. Lipid Peroxidation. Male. Mitochondria / metabolism. Rats. Rats, Wistar. Superoxide Dismutase / metabolism. Tumor Burden / drug effects. bcl-X Protein / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506872.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bcl2l1 protein, rat; 0 / Cyclooxygenase 2 Inhibitors; 0 / Free Radical Scavengers; 0 / Pyrazoles; 0 / Sulfonamides; 0 / bcl-X Protein; EC 1.11.1.6 / Catalase; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Ptgs2 protein, rat; EC 1.15.1.1 / Superoxide Dismutase; EC 2.5.1.18 / Glutathione Transferase; JCX84Q7J1L / Celecoxib
  •  go-up   go-down






Advertisement